GlassScriptPhysician profile
Michael C Kreager
NPI 1609850791
$3,563.53
in general payments reported to CMS, 2019-2025
22 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $285 · 2021: $475 · 2022: $473 · 2023: $591 · 2024: $766 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.99 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $620.01 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $409.04 | 2019-2024 | Brilinta, Farxiga, Airsupra |
| Novo Nordisk INC | $364.00 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $320.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $285.41 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.08 | 2020-2022 | |
| Amgen INC. | $213.07 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $197.53 | 2019-2024 | |
| Kestra Medical Technology Services, INC. | $142.05 | 2022-2025 | Assure Wcd |
| Biotronik INC. | $107.21 | 2022-2024 | Amvia Edge |
| Aimmune Therapeutics, INC. | $104.52 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $103.97 | 2024 | Watchman Access System |
| Heartflow, INC. | $87.17 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $69.31 | 2019-2020 | |
| Amarin Pharma, INC. | $61.33 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $47.81 | 2019-2020 | |
| Lilly USA, LLC | $40.42 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.90 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $32.77 | 2024-2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $26.77 | 2021 | |
| Abbvie INC. | $23.49 | 2021 | |
| Chiesi USA, INC. | $20.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kreager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.